Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study

No abstract is available for this paper.

• Publication year

  2004

• Venue

  HIV Medicine

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1468-1293.2004.00233.xPMID 15369509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug resistance mutations and outcome of second‐line treatment in patients with first‐line protease inhibitor failure on nelfinavir‐containing HAART

  2003cited by this paper
• Drug resistance mutations in HIV-1.

  2003cited by this paper
• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine

  2003cited by this paper
• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

  2003cited by this paper
• K65R with and without S68: A New Resistance Profile in Vivo Detected in Most Patients Failing Abacavir, Didanosine and Stavudine

  2003cited by this paper
• Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.

  2003cited by this paper
• The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml

  2002cited by this paper
• Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

  2002cited by this paper
• A Randomized Trial Comparing Initial Haart Regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in Combination with Two Nucleoside Reverse Transcriptase Inhibitors

  2002cited by this paper
• Detection and documentation of actual and potential medication adherence problems in patients receiving combination therapies.

  2002cited by this paper
• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  2002cited by this paper
• In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

  2002cited by this paper
• Virologic Rebound on HAART in the Context of Low Treatment Adherence Is Associated With a Low Prevalence of Antiretroviral Drug Resistance

  2002cited by this paper
• Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

  2002cited by this paper
• Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

  2002cited by this paper
• Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

  2001cited by this paper
• International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

  2001cited by this paper
• Nonnucleoside Reverse Transcriptase Inhibitor Resistance

  2001cited by this paper
• Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals

  2001cited by this paper
• Improving on a Coin Toss To Predict Patient Adherence to Medications

  2001cited by this paper
• Genotypic and Phenotypic Resistance Patterns in Early-Stage HIV-1-Infected Patients Failing Initial Therapy with Stavudine, Didanosine and Nevirapine

  2001cited by this paper
• Drug Resistance Mutations in HIV-1-Infected Subjects during Protease Inhibitor-Containing Highly Active Antiretroviral Therapy with Nelfinavir or Indinavir

  2000cited by this paper
• Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

  2000cited by this paper
• Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

  2000cited by this paper
• Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

  2000cited by this paper
• Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1

  1999cited by this paper
• The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.

  1999cited by this paper

• Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries

  2025cites this paper
• Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients

  2022cites this paper
• Evaluation of C-terminal p7 (NC)-p6 Gag genetic variants among HIV-1 non-B subtypes in a subset of Cameroonian patients

  2021cites this paper
• Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya

  2020cites this paper
• Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon

  2017cites this paper
• Efavirenz as component of initial combination antiretroviral therapy – Data from the Polish Observational Cohort of HIV/AIDS Patients (POLCA) Study Group

  2016cites this paper
• Estimation of the size and characteristics of HIV-positive populations in Europe

  2015cites this paper
• PhD thesis Non-HIV determinants of outcome in Danish HIV-infected patients: Impact of study participation, body fat distribution and family-related factors

  2015cites this paper
• Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review.

  2014cites this paper
• A mixed methods evaluation of the effectiveness of a nurse-led palliative care intervention for HIV positive patients on ART in Mombasa, Kenya

  2014cites this paper
• Burden of Nonnucleoside Reverse Transcriptase Inhibitor Resistance in HIV-1-Infected Patients: A Systematic Review and Meta-Analysis

  2014cites this paper
• Long-Term Efficacy of First Line Antiretroviral Therapy in Indian HIV-1 Infected Patients: A Longitudinal Cohort Study

  2013cites this paper
• Translational genomics of HIV-1 subtype C in India : molecular phylogeny and drug resistance

  2013cites this paper
• Comparing Adherence to Two Different HIV Antiretroviral Regimens: An Instrumental Variable Analysis

  2012cites this paper
• Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients

  2012cites this paper
• Design and Characterization of Novel Peptide-Coated Lipid Nanoparticles for Targeting Anti-HIV Drug to CD4 Expressing Cells

  2012cites this paper
• Unboosted Atazanavir for Treatment of HIV Infection

  2012cites this paper
• Optimized Antiretroviral Therapy with Darunavir/Ritonavir, Etravirine and/or Raltegarvir: A Salvage Therapy Option in HIV-1 Infected Patients with Long-Term Therapeutic Failures, about 23 Cases

  2012cites this paper
• Work-related Barriers and Facilitators to Antiretroviral Therapy Adherence in Persons Living with HIV Infection

  2011cites this paper
• Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

  2011cites this paper
• CD4+ T-Cell Counts and Plasma HIV-1 RNA Levels Beyond 5 Years of Highly Active Antiretroviral Therapy

  2011cites this paper
• Developing useful highly active antiretroviral therapy adherence measures for India: the Prerana study.

  2010cites this paper
• Poor performance of bioinformatics programs for genotypic prediction of coreceptor usage of HIV-1 group O isolates.

  2010cites this paper
• Unplanned ART Treatment Interruption in South Africa: what can we do to minimise the long-term risks?

  2010cites this paper
• Developing Useful HAART Adherence Measures for India: The Prerana Study

  2010cites this paper
• Assessing the Viorologic and Adherence Benefits of Patient-Selected HIV Treatment Partners in a Resource-limited Setting

  2009cites this paper
• Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a Once-Daily Efavirenz-Based Regimen in Treatment-Naïve HIV-1–Infected Patients Over 96 Weeks

  2009cites this paper
• Inhibitors of the Human Immunodeficiency Virus Protease

  2009cites this paper
• P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.

  2009cites this paper
• Unplanned ART treatment interruptions in Southern Africa: a literature review

  2009cites this paper
• Influences on adherence in African American women with HIV

  2008cites this paper
• Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression

  2008cites this paper
• Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines?

  2008cites this paper
• The Benefits of Women-Only HIV Support Groups

  2008cites this paper
• Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.

  2007cites this paper
• Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and Naive Pregnant Women in New York City During 1991 to Early 2001

  2007cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are Limited

  2007cites this paper
• the HIV-infected population: An observational study

  2006cites this paper
• HIV in Denmark and Greenland, 1995–2004, the effect of highly active antiretroviral therapy and characteristics of the HIV-infected population: an observational study

  2006cites this paper
• Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation.

  2006cites this paper
• ‘Simply forgot’ is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence

  2006cites this paper
• Chapter 1

  2005cites this paper
• Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil

  2005cites this paper
• Declining Prevalence of HIV-Infected Individuals at Risk of Transmitting Drug-Resistant HIV in Denmark during 1997–2004

  2005cites this paper
• Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals

  2005cites this paper
• Author Index

  2004cites this paper